<SEC-DOCUMENT>0001193125-22-153484.txt : 20220518
<SEC-HEADER>0001193125-22-153484.hdr.sgml : 20220518
<ACCEPTANCE-DATETIME>20220518060759
ACCESSION NUMBER:		0001193125-22-153484
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220518
FILED AS OF DATE:		20220518
DATE AS OF CHANGE:		20220518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		22936966

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d348482d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;18, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B><A HREF="d348482dex991.htm">Immutep Appoints Leading Oncologists to its Clinical Advisory Board</A></B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 18, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d348482dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348482g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Appoints
Leading Oncologists to its Clinical Advisory Board </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>18 May </B><B>2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM;
NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the
Company&#146;s Clinical Advisory Board (CAB). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CAB serves as a strategic resource to Immutep as the Company continues to advance its pipeline of LAG-3
programs, including combination therapy programs for lead product candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO
&amp; CMO, Dr. Frederic Triebel, commented:</B> &#147;We are privileged to have a group of leading oncologists on our Clinical Advisory Board and are pleased to welcome several new members. The CAB&#146;s experience in the development of
ground-breaking new cancer therapies will be invaluable as we look to advance efti into important late-stage development programs. In the coming months, we expect the CAB will particularly focus on our programs addressing metastatic breast and
non-small cell lung carcinomas.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new appointments to Immutep&#146;s CAB are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Scott Anton</B><B>ia</B><B>, M.D., Ph.D.</B> is recognised as a global leader in the development of immunotherapy for lung cancer. He
currently serves as the director of the Duke Cancer Institute (DCI) Center for Cancer Immunotherapy and is a member of the Thoracic Oncology disease group as Professor of Medical Oncology. He previously served as the chairman of the Department of
Thoracic Oncology at H. Lee Moffitt Cancer Center. He has served as the global principal investigator for the practice-changing Pacific study, which established, as the new global standard of care, anti-PDL1 as consolidative therapy after combined
chemo-radiation therapy for locally advanced non-small cell lung cancer. He was also the lead investigator of trials that established the clinical activity of immunotherapy for small cell lung cancer. For the past 27 years, Professor Antonia has
directed a translational research program with the overall goal to develop immunotherapeutic strategies for the treatment of cancer patients. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Leisha A Emens, M.D., Ph.D.</B><B> </B>is a Professor of Medicine at the UPMC Hillman Cancer Center. She received her MD/PhD in the Medical
Scientist Training Program (MSTP) at Baylor College of Medicine, and completed postgraduate training at the National Cancer Institute, the University of Texas at Southwestern, and Johns Hopkins University. She joined the faculty at Johns Hopkins
University in 2001, where she rose to the rank of Associate Professor of Oncology before joining the UPMC Hillman Cancer Center. She is a medical oncologist focused on breast cancer and is internationally recognised for her work in breast cancer
immunotherapy. She developed and tested a vaccine for breast cancer patients, and more recently has played a key role in the development of the anti-PD-L1 agent atezolizumab for triple negative breast cancer and HER2+ breast cancer. Dr. Emens was a
member of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep
Limited</B>, Level 33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348482g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the FDA Advisory Committee on Cellular, Tissue, and Gene Therapies (CTGTC) from 2012 to 2016. She is an active member of ASCO, AACR, and SITC, and is a member of the Cancer Immunology (CIMM)
Steering Committee of the AACR. Dr. Emens serves as Vice President of the Society for Immunotherapy of Cancer (SITC) and will ascend to the role of SITC President in 2023. She also serves as section editor for Journal for the Immunotherapy of Cancer
(JITC). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Martin </B><B>Forster</B><B>, M.D., Ph.D.</B><B>,</B> is an associate professor at University College London (UCL) and
consultant medical oncologist at University College Hospital. He specialises in lung cancer, thoracic and head and neck cancers and has a particular interest in drug development and in using the increasing understanding of cancer biology to design
studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. Professor Forster is a core member of the lung and head and neck cancer teams and runs a research-based practice, being principal
investigator or chief investigator for over 50 early and late-phase clinical trials, from first-in-human to registration Phase III trials. Professor Forster is the current clinical lead for the UCL Experimental Cancer Medicine Centre (ECMC) and
clinical lead for cancer research at the University College London Hospitals (UCLH). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Hans Wildiers, M.D., Ph.D.,</B> is a dedicated
breast cancer researcher and medical oncologist. He has been a staff member at the Department of Medical Oncology at the University Hospital Leuven, Belgium, since 2004. In addition, he coordinates the Leuven Multidisciplinary Breast Centre since
2015. Professor Wildiers has coordinated several academic studies in the field of breast cancer and geriatric oncology and authored more than 300 peer reviewed papers. He has also been active on the board the International Society of Geriatric
Oncology (SIOG), for many years, including serving as its president from November 2018 to October 2020. In addition, from 2009 to 2015, Professor Wildiers chaired the European Organisation for the Research and Treatment of Cancer&#146;s (EORTC) task
force on cancer in the elderly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information on Immutep&#146;s CAB may be found here: <U>https://www.immutep.com/about-us/leadership-team.html</U>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active
biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment
options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble LAG-3 fusion protein (LAG-3Ig), which
is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune
response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep
Limited</B>, Level 33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348482g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep
Limited</B>, Level 33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g348482g28v83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g348482g28v83.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #\ Q@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MYX__ "1K)<1.@DCDC:(C<LJNIC*C^(.#M*^X.*ULE]I*W0V4Z3CSJI&WJO\
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MN=/UC3)9)HQ<(P\N1B79!/'- Z<X-@V/M+]I?7UU7]GFY\0:5//;P:R?!M]
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M?K7MX>/)0I1O\4(V_P# ;GW&6+_A/P<>5)JE3VVT@CX>L%\O]I!P. OQ%U'
M';.H7K']6KP:<YO,XPB[)5.7_P !O?\ (_.8P<>,)57*T(XN226^[6VBZGVC
M\3E#?#OQJI ('AG62,]F2PG=3^!(_*O=Q,FL/6[)27X'Z'FJ3RW&\]VHT)M=
M[\DK/IY'S'^R@<:KXT7M_9NA_F+G4 /YUY&1/7$]+*/_ +<?'\#\L*F.4')K
MEPVDNCM6VU>YQ7BG_DX\?]CYX9_]&Z-6-1I9FKWM[1;;]#S<PD_];E&"7-]8
MHI<VVLJ2??IY'W3XN0GPIXD4A67_ (1W6]RMW_XEEQCM[FO?KJ+HUMU[C_\
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1YQ@@DV#8^QJ "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
